Ad hoc: Medigene and SynCore enter into Co-Development and Commercialization Agreement for EndoTAG®-1

06.07.12 17:00
Ad hoc: <strong>Medigene</strong> and SynCore enter into Co-Development and Commercialization Agreement for EndoTAG®-1

MediGene AG /Ad hoc: Medigene and SynCore enter into Co-Development and Commercialization Agreement for EndoTAG®-1 . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

  • SynCore receives exclusive rights to co-develop and commercialize EndoTAG®-1 in Asia, Australia and New Zealand  

  • Medigene retains all US, European and remaining RoW rights 

  • Medigene will receive an upfront, milestone payments and royalties  

  • Medigene plans global pivotal phase III trial in triple-negative breast cancer (TNBC) 

  • SynCore will assume costs for the Asian part of the global pivotal phase III trial  

Martinsried/Munich, July 6, 2012. Medigene AG (Frankfurt: MDG, Prime Standard) announced that it has granted exclusive rights for co-development and commercialization of EndoTAG®-1 in Asia, Australia and New Zealand to SynCore Biotechnology Co., Ltd. ("SynCore"), a subsidiary of the Sinphar Pharmaceutical Group (Taiwan Stock Exchange, Symbol: 1734).

Medigene plans a pivotal global phase III trial of EndoTAG®-1 in triple-negative breast cancer (TNBC) with the aim of achieving worldwide market approval. Under the terms of the agreement, SynCore will fund the Asian part of the clinical trial, representing about 50% of the total number of patients to be included. Subject to clinical trial approval, approximately 400 patients are expected to be enrolled in the global pivotal phase III trial in TNBC. Furthermore, Medigene receives an upfront payment from SynCore and is eligible to payments upon certain development and approval milestones as well as royalties. Medigene retains all US, European and remaining rest-of-the-world (RoW) rights to EndoTAG®-1 with the ability to grant further licenses. Medigene anticipates submission for market approval for EndoTAG®-1 in 2018.

The agreement does not impact Medigene's financial guidance for 2012 and the management confirms that the company's funding is expected to be secured beyond 2013.

For more information please see today's press release at

- End -


Julia Hofmann & Kerstin Langlotz

Tel.: +49 - 89 - 20 00 33 - 33 01

Fax: +49 - 89 - 20 00 33 - 29 20


ad hoc release as pdf

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: MediGene AG via Thomson Reuters ONE


--- End of Message ---

MediGene AG

Lochhamer Strasse 11 Martinsried / München Germany

WKN: 502090;ISIN: DE0005020903;

Listed: Freiverkehr in Börse Stuttgart,

Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,

Freiverkehr in Börse Düsseldorf,

Freiverkehr in Bayerische Börse München,

Freiverkehr in Niedersächsische Börse zu Hannover,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse;


Breaking News

Kurs- und weitere Informationen zum Thema:


Aktuelle Diskussionen zum Thema:

Medigene - es kann los gehen - ... (19.06.18)
Medigene - ... (19.06.18)
Medigene - Sachliche und ... (13.06.18)

Aktuelle Nachrichten zum Unternehmen:

Medigene-Aktie: MDG1011-klinische. (18.06.18)
Evotec, Medigene, MorphoSys, Epig. (17.06.18)
Medigene-Aktie: Wann endet die a. (16.06.18)
Medigene-Aktie: Leerverkäufer Oxf. (12.06.18)
Medigene-Aktie: Geduldig bleiben! A. (07.06.18)

Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

Weitere Meldungen
09.07 Ad hoc: Linde AG: Ad-hoc-.
09.07 Ad hoc: Vorstand der Comp.
09.07 Ad hoc: Oceanica AG: Amt.
09.07 Ad hoc: Solarparc AG: Hand.
09.07 Ad hoc: Kremlin AG: Portfo.
09.07 Ad hoc: Wolford AG: Ad h.
09.07 Ad hoc: nebag ag / Kapital.
06.07 Ad hoc: WILEX AG entsch.
06.07 Ad hoc: Medigene and SynC.
06.07 Ad hoc: Medigene und SynC.
06.07 Ad hoc: WMF Württemberg.
06.07 DGAP-WpÜG: Übernahmeang.
06.07 Ad hoc: Leclanché startet d.
05.07 Ad hoc: _wige Media: Integ.
05.07 Ad hoc: LEWAG Holding A.
05.07 Ad hoc: FAST Casualwear .
05.07 Ad hoc: Schweizer Electroni.
05.07 Ad hoc: TOM TAILOR Hold.
05.07 Ad hoc: AEVIS Holding SA.
04.07 UK-Regulatory: VOLKSWAG.
04.07 Ad hoc: VOLKSWAGEN A.
04.07 Ad hoc: Porsche Automobil .
04.07 Ad hoc: Praktiker AG: Pers.
04.07 Ad hoc: Praktiker AG: Pers.
04.07 Ad hoc: Ming Le Sports AG.
04.07 Ad hoc: IBS AG excellence.
04.07 Ad hoc: TOM TAILOR Hold.
04.07 Ad hoc: Hansa Group AG: .
04.07 Ad hoc: Catalis SE: Catalis .
04.07 Ad hoc: Unternehmens Inves.

Welche Social Networks nutzen Sie meistens?
Linked in

Stimmen: 37203 , Ergebnis

Status: nicht eingeloggt

Registrieren | Passwort vergessen?
Im Bereich Nachrichten:
Adidas: Außer Spesen nichts gewesen!
Experte: Stefan Hofmann, STOCK-WORLD
Schweizer telefonieren ...
Volker Gelfarth, (14:20)
Experte: Volker Gelfarth,
Der Gewinn liegt im Einkauf, (14:01)
Der Pep fürs Depot - ...
Ingrid Heinritzi, (13:39)
Experte: Ingrid Heinritzi,
Wissen: Welche ...
Robert Sasse, (13:23)
Experte: Robert Sasse,
Tesla: Reif für eine ...
Frank Sterzbach, (13:11)
Experte: Frank Sterzbach,
DAX®: Index nahe ...
S. Feuerstein, Hebelzertifikate-Trader (13:00)
Experte: S. Feuerstein, Hebelzertifikate-Trader
Börsengeflüster: #NESTLÉ – ...
WTI-Öl: Sanktionen drohen
Jürgen Sterzbach, (12:42)
Experte: Jürgen Sterzbach,
Die Börse im Bann der WM
Sven Weisenhaus, Stockstreet GmbH (12:02)
Experte: Sven Weisenhaus, Stockstreet GmbH
Bonterra Resources ...
Björn Junker, (11:52)
Experte: Björn Junker,
Wirecard und DAX – ...
Feingold-Research, (11:20)
Experte: Feingold-Research,
EUR/USD - Stopp ...
Christian Zoller, (11:02)
Experte: Christian Zoller,
Niquet's World
Neues vom Portal
Aktienmarkt bietet zahlreiche Möglichkeiten fürs Geld verdienen
Letzte Börsen-Meldung
Letzte Börsen-Analyse
Top-Klicks News
Top-Klicks Analysen